Stockscreener 앱 받기
2.32
1.28%
-0.03
전일 마감가:
$2.35
열려 있는:
$2.36
하루 거래량:
287.13K
Relative Volume:
0.46
시가총액:
$130.71M
수익:
$76.19M
순이익/손실:
$-1.61M
주가수익비율:
232.00
EPS:
0.01
순현금흐름:
$28.98M
1주 성능:
+2.65%
1개월 성능:
-12.78%
6개월 성능:
-19.72%
1년 성능:
+110.91%
1일 변동 폭
$2.30
$2.36
1주일 범위
$2.255
$2.39
52주 변동 폭
$0.5052
$3.22
Spero Therapeutics Inc Stock (SPRO) Company Profile
명칭
Spero Therapeutics Inc
전화
857-242-1600
주소
675 MASSACHUSETTS AVENUE, CAMBRIDGE, MA
SPRO을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
SPRO
Spero Therapeutics Inc
|
2.32 | 132.40M | 76.19M | -1.61M | 28.98M | 0.01 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.04 | 113.14B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.29 | 78.49B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
877.94 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.55 | 54.51B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
197.01 | 41.64B | 447.02M | -1.18B | -906.14M | -6.1812 |
Spero Therapeutics Inc Stock (SPRO) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-12-20 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2022-09-23 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2021-10-01 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2021-01-22 | 재확인 | H.C. Wainwright | Buy |
| 2020-12-16 | 개시 | Berenberg | Buy |
| 2020-09-29 | 개시 | Evercore ISI | Outperform |
| 2019-11-05 | 재확인 | H.C. Wainwright | Buy |
| 2019-09-09 | 개시 | Janney | Buy |
| 2018-02-09 | 개시 | Cantor Fitzgerald | Overweight |
| 2017-11-27 | 개시 | BofA/Merrill | Neutral |
| 2017-11-27 | 개시 | Oppenheimer | Outperform |
| 2017-11-27 | 개시 | Stifel | Buy |
모두보기
Spero Therapeutics Inc 주식(SPRO)의 최신 뉴스
Spero Therapeutics (NASDAQ:SPRO) Upgraded to "Buy" at Wall Street Zen - MarketBeat
What analysts say about Spero Therapeutics Inc stockInsider Trading Compliance & Minimal Investment Trading - earlytimes.in
Spero Therapeutics, Inc. (SPRO) Reports Q1 Loss, Misses Revenue Estimates - sharewise.com
Spero Therapeutics (NASDAQ:SPRO) Stock Rating Lowered by Wall Street Zen - Defense World
Can Spero Therapeutics Inc. (2HA) stock test all time highsMarket Risk Report & Free Low Drawdown Momentum Trade Ideas - Newser
Will Spero Therapeutics Inc. (2HA) stock benefit from sector leadership2025 Top Gainers & Free Weekly Watchlist of Top Performers - Newser
Why Spero Therapeutics Inc. stock is popular among millennials2025 Market Overview & Community Consensus Picks - Newser
How Spero Therapeutics Inc. (2HA) stock behaves in tightening cycles2025 Trading Recap & Intraday High Probability Alerts - Newser
How Spero Therapeutics Inc. stock benefits from global expansionStock Surge & Risk Adjusted Buy/Sell Alerts - Newser
How Spero Therapeutics Inc. (2HA) stock performs during market turbulenceJuly 2025 Reactions & Short-Term High Return Strategies - Newser
Published on: 2025-12-02 04:03:46 - Newser
Will Spero Therapeutics Inc. (2HA) stock remain on Wall Street radar2025 Price Momentum & Reliable Volume Spike Trade Alerts - Newser
Spero Therapeutics, Inc. (SPRO) Reports Q4 Loss, Tops Revenue Estimates - MSN
Spero Therapeutics (NASDAQ:SPRO) Upgraded to “Buy” at Wall Street Zen - Defense World
Can Silver Oak India Limited Maintain Its Share of Global Market for Its ProductStock Buy Signals & Get Free Training on Technical Indicators - earlytimes.in
Spero Therapeutics announces inducement grant under Nasdaq listing rule - TipRanks
Spero Therapeutics (SPRO) Awards New Employee with Restricted St - GuruFocus
Spero Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Enidnews.com
Breakout Move: Will Spero Therapeutics Inc. stock reach all time highs in 2025 - moha.gov.vn
Aug Mood: Will Spero Therapeutics Inc. stock reach all time highs in 2025July 2025 Patterns & AI Forecasted Entry and Exit Points - BỘ NỘI VỤ
Spero Therapeutics (NASDAQ:SPRO) Shares Cross Above 200-Day Moving Average – Should You Sell? - Defense World
Global NTM Infections Pipeline Poised for Growth as Breakthrough Therapies Advance Toward Late-Stage Development, states DelveInsight - The Globe and Mail
What is Spero Therapeutics Inc (SPRO) Stock Return on Shareholders’ Capital? - Setenews
Why Spero Therapeutics Inc. (2HA) stock is favored by hedge fundsJuly 2025 Final Week & Free Weekly Chart Analysis and Trade Guides - newser.com
Will Spero Therapeutics Inc. stock attract ESG investorsWeekly Trade Recap & Verified Swing Trading Watchlists - newser.com
How Spero Therapeutics Inc. (2HA) stock reacts to stronger dollarBear Alert & Low Drawdown Momentum Trade Ideas - newser.com
What technical patterns form on Spero Therapeutics Inc. (2HA) stock chartsWeekly Profit Recap & AI Driven Price Forecasts - newser.com
Will Spero Therapeutics Inc. stock deliver strong dividend growth2025 Risk Factors & AI Forecasted Entry and Exit Points - newser.com
Will Spero Therapeutics Inc. benefit from macro trendsEntry Point & Safe Entry Zone Tips - newser.com
Published on: 2025-11-19 17:07:59 - newser.com
How Spero Therapeutics Inc. stock reacts to inflationary pressuresTrade Analysis Summary & Real-Time Price Movement Reports - newser.com
Published on: 2025-11-19 18:54:15 - newser.com
Why Spero Therapeutics Inc. stock is favored by pension fundsJuly 2025 Big Picture & Safe Entry Momentum Stock Tips - newser.com
Will Spero Therapeutics Inc. stock pay special dividendsMarket Growth Summary & Real-Time Volume Trigger Notifications - newser.com
How Spero Therapeutics Inc. stock compares to industry benchmarks - newser.com
Spero Therapeutics: A High-Stakes Bet on a Single Drug - Ad-hoc-news.de
Is Spero Therapeutics Inc. (2HA) stock undervalued historicallyWeekly Market Report & Accurate Intraday Trading Signals - newser.com
Spero Therapeutics Inc (SPRO) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.08%
0.91%
자본화:
|
볼륨(24시간):